Pharma investors who may have hoped for a hepatitis C virus (HCV) contender to surface from Merck & Co. Inc. likely were disappointed as Gilead Science Inc.'s backers cheered the less-than-spectacular though eagerly awaited results from the trial known as C-SWIFT.